公开(公告)号：US20170281734A1

公开(公告)日：2017-10-05

申请号：US15455043

申请日：2017-03-09

Applicant: Bioverativ Therapeutics Inc.

Inventor： Kevin MALONEY ,  Daniel Gage ,  Ahmad Abdul-Fattah

IPC: A61K38/37 ,  C07K14/755 ,  C07K16/28

Abstract: The present invention provides a formulation of a Factor VIII polypeptide, e.g., FVIII-Fc, and methods of using the same. The FVIII polypeptide can be a recombinant FVIII protein, a short-acting FVIII protein, or a long-acting FVIII protein. The pharmaceutical formulation comprising a FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.

公开(公告)号：US20210069300A1

公开(公告)日：2021-03-11

申请号：US16993979

申请日：2020-08-14

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Kevin MALONEY ,  Daniel GAGE ,  Ahmad ABDUL-FATTAH

IPC: A61K38/37 ,  C07K14/755 ,  C07K16/28

Abstract: The present invention provides a formulation of a Factor VIII polypeptide, e.g., FVIII-Fc, and methods of using the same. The FVIII polypeptide can be a recombinant FVIII protein, a short-acting FVIII protein, or a long-acting FVIII protein. The pharmaceutical formulation comprising a FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.